Search results
Showing 376 to 390 of 1373 results for social care
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
In development Reference number: GID-TA11793 Expected publication date: 18 November 2026
This manual sets out the process for how new guidance topics and updates to existing NICE guidance are identified, prioritised and routed at NICE, and the decision-making framework used by the NICE prioritisation board
In development Reference number: GID-TA11254 Expected publication date: 04 March 2026
In development Reference number: GID-TA11768 Expected publication date: 03 September 2026
This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years. Care of babies and children born preterm or with low birth weight is not covered. The guideline does not give detailed advice on what constitutes a healthy diet.
In development Reference number: GID-TA11566 Expected publication date: TBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]
In development Reference number: GID-TA11630 Expected publication date: TBC
Our resource planner tool to help you plan for and implement NICE guidance.
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Awaiting development Reference number: GID-TA10638 Expected publication date: TBC
This guide describes the process NICE uses to develop NICE quality standards
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Initial education in adrenaline auto-injector use
- Quality statement 2: Referral to specialist allergy services after emergency treatment
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4: Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
In development Reference number: GID-TA11823 Expected publication date: TBC
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards